TABLE 2.

Summary of reported cases of MRSA bacteremia with failed daptomycin treatment^a

Age of patient (yr)/gender	Underlying condition(s)	Source(s) of bacteremia	Daptomycin dosage	Time until development of nonsusceptibility after usage (days)	Vancomycin MIC (μg/ml)	Daptomycin MIC (μg/ml)	Salvage treatment	Outcome(s)	Molecular method for comparison	Reference
86/F	Knee prosthesis	Prosthetic joint infection, complication with epidural abscess and vertebral osteomyelitis	6 mg/kg/day	35	NA	4	NA	NA	PFGE	8
61/F	Cardiac surgery	Sternal osteomyelitis, vertebral osteomyelitis	6 mg/kg/day	42	NA	4	NA	NA	PFGE	9
91/M	Pacemaker implantation	Pacemaker wire infection	7 mg/kg/day	11	2	2	NA	Died	PFGE
NA	IVDU	Right-side IE	1.5 mg/kg/q12h	4	NA	5	NA	NA	NA	11
54/M	HCV-related liver cirrhosis	Portal vein septic thrombosis	4 mg/kg/q12h	27	1	2	Linezolid, and then vancomycin plus gentamicin	Hospice care, microbiological success	NA	12
61/M	AML post-HSCT with GVHD	Vertebral osteomyelitis and diskitis	6 mg/kg/day	20	NA	4	Linezolid, and then vancomycin plus rifampin	Died of AML relapse; microbiological success	PFGE	13
64/F	DM, breast cancer	Septic arthritis, leg abscess over surgical site	6 mg/kg/day	—b	≤2	4	Linezolid	Survived, cured	NA	17
66/M	HCV-related liver cirrhosis, ESRD	Left-side IE and probable septic phlebitis	6 mg/kg/day	0c	4	4	Linezolid	Died of candidemia; microbiological success	PFGE	Current study

^aF, female; M, male; NA, not applicable; IVDU, intravenous-drug user; HCV, hepatitis C virus; AML, acute myeloblastic leukemia; HSCT, hemopoietic stem cell transplantation; GVHD, graft versus host disease; DM, diabetes mellitus; ESRD, end-stage renal disease; IE, infective endocarditis; q12h, every 12 h; PFGE, pulse-field gel electrophoresis.

^b—, for this case, the time period included 28 weeks over the course of 2 years.

^cNonsusceptible at initiation.